- Home
- YQ vs ASBP Comparison
YQ vs ASBP Comparison
Compare YQ & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- ASBP
- Stock Information
- Founded
- YQ 2012
- ASBP 2021
- Country
- YQ China
- ASBP United States
- Employees
- YQ N/A
- ASBP N/A
- Industry
- YQ Other Consumer Services
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- ASBP Health Care
- Exchange
- YQ Nasdaq
- ASBP Nasdaq
- Market Cap
- YQ 15.2M
- ASBP 17.6M
- IPO Year
- YQ 2020
- ASBP N/A
- Fundamental
- Price
- YQ $1.89
- ASBP $0.24
- Analyst Decision
- YQ
- ASBP
- Analyst Count
- YQ 0
- ASBP 0
- Target Price
- YQ N/A
- ASBP N/A
- AVG Volume (30 Days)
- YQ 33.0K
- ASBP 363.3K
- Earning Date
- YQ 06-04-2025
- ASBP 05-24-2025
- Dividend Yield
- YQ N/A
- ASBP N/A
- EPS Growth
- YQ N/A
- ASBP N/A
- EPS
- YQ N/A
- ASBP N/A
- Revenue
- YQ $25,922,648.00
- ASBP N/A
- Revenue This Year
- YQ N/A
- ASBP N/A
- Revenue Next Year
- YQ N/A
- ASBP N/A
- P/E Ratio
- YQ N/A
- ASBP N/A
- Revenue Growth
- YQ 10.68
- ASBP N/A
- 52 Week Low
- YQ $1.26
- ASBP $0.32
- 52 Week High
- YQ $3.19
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- YQ 49.62
- ASBP N/A
- Support Level
- YQ $1.99
- ASBP N/A
- Resistance Level
- YQ $2.50
- ASBP N/A
- Average True Range (ATR)
- YQ 0.33
- ASBP 0.00
- MACD
- YQ -0.00
- ASBP 0.00
- Stochastic Oscillator
- YQ 25.23
- ASBP 0.00
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.